Leung Kam
National for Biotechnology Information, NLM, NIH, Bethesda, MD
Optical fluorescence imaging is increasingly used to monitor biological functions of specific targets in small animals (1-3). However, the intrinsic fluorescence of biomolecules poses a problem when fluorophores that absorb visible light (350–650 nm) are used. Near-infrared (NIR) fluorescence (650–900 nm) detection avoids the natural background fluorescence interference of biomolecules, providing a high contrast between target and background tissues. NIR fluorophores have wider dynamic range and minimal background fluorescence as a result of reduced scattering compared with visible fluorescence detection. They also have high sensitivity, resulting from low background fluorescence, and high extinction coefficients, which provide high quantum yields. The NIR region is also compatible with solid-state optical components, such as diode lasers and silicon detectors. NIR fluorescence imaging is a noninvasive complement to radionuclide imaging in small animals or with probes in close proximity to the target in humans (4). Among the various optical imaging agents, only indocyanine green (ICG), with NIR fluorescence absorption at 780 nm and emission at 820 nm, is approved by the United States Food and Drug Administration for clinical applications in angiography, blood flow evaluation, and liver function assessment (5-8). It is also under evaluation in several clinical trials for other applications, such as optical imaging and mapping of both the lymphatic vessels and lymph nodes in cancer patients for surgical dissection of tumor cells and endoscopic imaging of the pancreas and colon. The phosphorylation of glucose, an initial and important step in cellular metabolism, is catalyzed by hexokinases (HKs) (9). There are four HKs in mammalian tissues (HKI–HKIV). HKI, HKII, and HKIII have molecular weights of ~100,000 each; HKI is found mainly in the brain, and HKII is insulin-sensitive and is found in adipose and muscle cells. HKIV, also known as glucokinase, has a molecular weight of ~50,000 and is specific to the liver and pancreas. Most brain HK is bound to mitochondria, enabling coordination between glucose consumption and oxidation. Tumor cells are known to be highly glycolytic because of increased expression of glycolytic enzymes and HK activity (10), which was detected in tumors from patients with lung, gastrointestinal, and breast cancers. The HKs, by converting glucose to glucose-6-phosphate, help maintain the downhill gradient that results in the transport of glucose into cells through the facilitative glucose transporters (GLUT1–13) (11). GLUT1 is considered to be the main transporter of glucose uptake. GLUT4 and HKII are the major transporter and HK isoform in skeletal muscle, heart, and adipose tissue, wherein insulin promotes glucose utilization. HKIV is associated with GLUT2 in liver and pancreatic β cells. 2-Deoxy-d-glucose (2DG) was first developed to inhibit glucose utilization by cancer cells (12). HKs phosphorylate 2DG to 2DG-6-phosphate, which inhibits phosphorylation of glucose. 2-[F]Fluoro-2-deoxy-d-glucose ([F]FDG) was later developed for molecular imaging studies (13). FDG is moved into cells by glucose transporters, where it is phosphorylated by HK to FDG-6-phosphate. FDG-6-phosphate cannot be metabolized further in the glycolytic pathway and remains in the cells. Tumor cells do not contain a sufficient amount of glucose-6-phosphatase to reverse the phosphorylation. The elevated rates of glycolysis and glucose transport in many types of tumor cells and activated cells enhance the uptake of FDG in these cells relative to other normal cells. Positron emission tomography (PET) with [F]FDG has been used to assess alterations in glucose metabolism in brain, cancer, cardiovascular diseases, Alzheimer’s disease and other central nervous system disorders, and infectious, autoimmune, and inflammatory diseases (14-19). Various NIR dyes (such as cypate, Cy5.5, and IRDye800CW) were conjugated to 2DG (20-22) as optical imaging agents for imaging of glucose utilization in tumors in mice. Cypate is a reactive carbocyanine dye, which is derived from indocyanine green (ICG) (23). Cypate exhibits an absorbance maximum at 778 nm and an emission maximum at 805 nm, with a high extinction coefficient of 224,000 M−cm−. Cypate is a lipophilic dye and contains two carboxyl functional groups for covalent conjugation to the amino group of biomolecules. Guo et al. (24) evaluated cypate-2DG for NIR optical imaging in tumor-bearing mice.
光学荧光成像越来越多地用于监测小动物体内特定靶点的生物学功能(1 - 3)。然而,当使用吸收可见光(350 - 650 nm)的荧光团时,生物分子的固有荧光会带来问题。近红外(NIR)荧光(650 - 900 nm)检测可避免生物分子的自然背景荧光干扰,使靶组织与背景组织之间具有高对比度。与可见荧光检测相比,近红外荧光团由于散射减少,具有更宽的动态范围和最小的背景荧光。它们还具有高灵敏度,这源于低背景荧光,以及高消光系数,可提供高量子产率。近红外区域也与固态光学组件兼容,如二极管激光器和硅探测器。近红外荧光成像在小动物中是放射性核素成像的非侵入性补充,在人体中则是对靠近靶标的探针进行成像(4)。在各种光学成像剂中,只有吲哚菁绿(ICG),其在780 nm处吸收近红外荧光,在820 nm处发射,已被美国食品药品监督管理局批准用于血管造影、血流评估和肝功能评估的临床应用(5 - 8)。它也正在多项临床试验中接受评估,用于其他应用,如癌症患者淋巴管和淋巴结的光学成像和绘图,以进行肿瘤细胞的手术切除,以及胰腺和结肠的内镜成像。葡萄糖磷酸化是细胞代谢的初始且重要步骤,由己糖激酶(HKs)催化(9)。哺乳动物组织中有四种己糖激酶(HKI - HKIV)。HKI、HKII和HKIII的分子量均约为100,000;HKI主要存在于大脑中,HKII对胰岛素敏感,存在于脂肪和肌肉细胞中。HKIV,也称为葡萄糖激酶,分子量约为50,000,特异性存在于肝脏和胰腺中。大多数脑己糖激酶与线粒体结合,使葡萄糖消耗与氧化之间能够协调。已知肿瘤细胞由于糖酵解酶表达增加和己糖激酶活性增强而具有高度糖酵解性(10),这在肺癌、胃肠道癌和乳腺癌患者的肿瘤中已被检测到。己糖激酶通过将葡萄糖转化为葡萄糖 - 6 - 磷酸,有助于维持下坡梯度,从而导致葡萄糖通过易化葡萄糖转运蛋白(GLUT1 - 13)进入细胞(11)。GLUT1被认为是葡萄糖摄取的主要转运蛋白。GLUT4和HKII是骨骼肌、心脏和脂肪组织中的主要转运蛋白和己糖激酶同工型,其中胰岛素促进葡萄糖利用。HKIV在肝脏和胰腺β细胞中与GLUT2相关。2 - 脱氧 - d - 葡萄糖(2DG)最初是为抑制癌细胞的葡萄糖利用而开发的(12)。己糖激酶将2DG磷酸化为2DG - 6 - 磷酸,从而抑制葡萄糖的磷酸化。后来开发了2 - [F]氟 - 2 - 脱氧 - d - 葡萄糖([F]FDG)用于分子成像研究(13)。FDG通过葡萄糖转运蛋白进入细胞,在细胞内被己糖激酶磷酸化为FDG - 6 - 磷酸。FDG - 6 - 磷酸不能在糖酵解途径中进一步代谢,而是留在细胞内。肿瘤细胞中没有足够量的葡萄糖 - 6 - 磷酸酶来逆转磷酸化。许多类型的肿瘤细胞和活化细胞中糖酵解和葡萄糖转运速率的升高,相对于其他正常细胞,增强了这些细胞对FDG的摄取。使用[F]FDG的正电子发射断层扫描(PET)已用于评估脑、癌症、心血管疾病、阿尔茨海默病和其他中枢神经系统疾病以及感染性、自身免疫性和炎症性疾病中葡萄糖代谢的变化(14 - 19)。各种近红外染料(如cypate、Cy5.5和IRDye800CW)与2DG偶联(20 - 22),作为用于小鼠肿瘤中葡萄糖利用成像的光学成像剂。Cypate是一种反应性碳菁染料,它源自吲哚菁绿(ICG)(23)。Cypate在778 nm处有最大吸收峰,在805 nm处有最大发射峰,消光系数高达224,000 M−1cm−1。Cypate是一种亲脂性染料,含有两个羧基官能团,用于与生物分子的氨基进行共价偶联。郭等人(24)评估了cypate - 2DG在荷瘤小鼠中的近红外光学成像。